F. Longo Muñoz
8 Papers
10 Citations
F. Longo Muñoz is an academic researcher. The author has contributed to research in topics: Colorectal cancer & Medicine. The author has an hindex of 2, co-authored 7 publications.
Chat about Author
Papers
Applicability of the LIPI score to metastatic microsatellite instability high cancer patients treated with immune checkpoint inhibitors
P. Vuagnat,Edouard Auclin,Laura Mezquita,J. Adeva Alfonso,M.D.R. Vidal Tocino,F. Longo Muñoz,Y. El Dakdouki,P. Martin Romano,Capucine Baldini,Andreea Varga,Rocio Garcia-Carbonero,Benjamin Besse,Christophe Massard,Antoine Hollebecque +13 more
TL;DR: Poor LIPI is correlated with worse ICI outcomes (PFS, ORR) in MSI-H pts, identifying potentially a MSI-h subset of pts with no benefit from ICI.
6
2151 Timing of adverse events (AEs) in the Phase 3 RECOURSE trial of TAS-102 versus placebo in patients (pts) with metastatic colorectal cancer (mCRC)
Eiji Shinozaki,Stéphanie Laurent,Cristina Grávalos,Martín Benavides,F. Longo Muñoz,Hirokazu Mizuguchi,M. Wahba,M. Ychou,Fortunato Ciardiello,Salvatore Siena,Kensei Yamaguchi,Kei Muro,Tadamichi Denda,Yasushi Tsuji,Patrick J. Loehrer,H. J. Lenz,Niall C. Tebbutt,Robert J. Mayer,E. Van Cutsem,A. Ohtsu +19 more
5
Cisplatin/5-fluorouracil +/- panitumumab for patients with non-resectable, advanced or metastatic esophageal squamous cell cancer: A randomized phase III AIO/EORTC trial with an extensive biomarker program
Markus Moehler,Annett Maderer,Peter C. Thuss-Patience,Baruch Brenner,J. Hecker,F. Longo Muñoz,Johannes Meiler,Thomas J. Ettrich,R.D. Hofheinz,S.-E. Al-Batran,Arndt Vogel,Lothar Mueller,Manfred P. Lutz,Kersten Borchert,Richard Greil,M. Alsina,A. Karatas,E. Van Cutsem,Ralph Keller,Julian Larcher-Senn,Sylvie Lorenzen +20 more
2
Efficacy of adjuvant chemotherapy for elderly patients with colon cancer
M. Villamayor Delgado,C. Saavedra Serrano,E. Corral de la Fuente,A. Barquín García,O. Martínez Saez,R. Martín Huertas,J. Serrano Domingo,J. Molina Cerrillo,F. Longo Muñoz,V. Pachón Olmos,M. Rodriguez Garrote,P. Reguera Puertas,M. Vaz,Alfredo Carrato,R. Ferreiro Monteagudo +14 more
2
113P Pembrolizumab in microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors: An update of the phase II KEYNOTE-158 trial
Miréia Florencio Maio,Paolo A. Ascierto,D. Motola Kuba,Nicolas Penel,P. A. Cassier,Giovanni M. Bariani,Ana De Jesus-Acosta,Tashiko Doi,F. Longo Muñoz,William R. Miller,D. Oh,Marsha Gottfried,Luyang Yao,Fan Jin,Alexander Gozman,Aurélien Marabelle +15 more
TL;DR: Pembrolizumab provides durable tumor responses in patients (pts) with advanced MSI-H/dMMR solid tumors as mentioned in this paper , with a median follow-up approximate of 54 months.
1